

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 March 2023 (16.03.2023)



(10) International Publication Number
WO 2023/039489 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) C12N 15/09 (2006.01)
C12N 5/10 (2006.01)

(21) International Application Number:

PCT/US2022/076137

(22) International Filing Date:

08 September 2022 (08.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/241,836 08 September 2021 (08.09.2021) US

(71) Applicant: **ORCHARD THERAPEUTICS (EUROPE) LIMITED** [GB/GB]; 108 Cannon Street, London EC4N 6EU (GB).

(72) Inventor; and

(71) Applicant: **WOLFE, Jia, L.** [US/US]; 28 Hollywood Road, Winchester, MA 01890 (US).

(72) Inventors: **MARKS-BLUTH, Jonathon, Simeon**; 102b Hanley Road, London N4 3DW (GB). **GASPAR, Bobby**; 5, Ardbeg Road, London SE24 9JL (GB). **SAGOO, Pervinder**; 18 St Vincent Drive, St Albans AL1 5SJ (GB). **RECH, Chiara**; 257 Fulham Palace Road, London SW6 6TP (GB).

(74) Agent: **BELLIVEAU, Michael, J.**; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES

FIG. 1A



(57) Abstract: Described herein are compositions and methods for treating a subject having or at risk of developing an autoimmune disease. Using the compositions and methods of the disclosure, a patient may be provided pluripotent hematopoietic cells that are genetically modified to express an autoantigen-binding moiety (e.g., a chimeric antigen receptor) under the control of lineage-specific transcription regulatory elements that are active in CD4+CD25+ regulatory T (Treg) cells (e.g., a Foxp3 promoter).

WO 2023/039489 A1